MOG (35-55) Peptide: Gold-Standard Inducer for EAE & Multiple Sclerosis Models

Executive Summary: MOG (35-55) is a truncated peptide from myelin oligodendrocyte glycoprotein, widely used to induce experimental autoimmune encephalomyelitis (EAE), the leading animal model for multiple sclerosis (MS) research (Xu et al., 2025). This peptide robustly triggers T and B cell-mediated demyelination in susceptible mouse strains (APExBIO). It is highly encephalitogenic, especially in HLA-DR2-transgenic, NOD/Lt, and C57BL/6 mice. MOG (35-55) enables benchmarking of neuroinflammation, immune cell responses, and therapeutic efficacy in preclinical autoimmune disease studies. Reliable protocols and storage conditions are critical for reproducibility (IGH-1, 2023).

Biological Rationale

Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system (CNS) characterized by demyelination and neuroinflammation. Experimental autoimmune encephalomyelitis (EAE) is the primary animal model for MS, recapitulating key features such as relapsing-remitting neurological deficits and plaque-like demyelination (Xu et al., 2025). Myelin oligodendrocyte glycoprotein (MOG) is a CNS-specific antigen, and its 35–55 amino acid peptide fragment (MOG (35-55)) is highly encephalitogenic in mice. MOG (35-55) induces robust T cell and B cell responses, facilitating mechanistic studies of autoimmune demyelination, neuroinflammatory signaling, and candidate MS therapies (APExBIO).

Mechanism of Action of MOG (35-55) Peptide

MOG (35-55) acts as a potent immunogen when administered with Complete Freund's Adjuvant (CFA). It is presented by antigen-presenting cells on MHC class II molecules, especially in HLA-DR2 transgenic mice, initiating CD4+ T cell activation. The peptide triggers autoreactive T cell proliferation and cytokine release (notably IFN-γ and IL-17), leading to CNS infiltration, demyelination, and axonal damage. Concurrently, B cell activation and anti-MOG autoantibody production exacerbate pathology. The resulting neuroinflammatory cascade involves increased NADPH oxidase activity and matrix metalloproteinase-9 (MMP-9) expression, promoting oxidative stress and blood-brain barrier disruption. Recent evidence shows modulation of type I interferon signaling—particularly via STAT1/STAT2 pathways—plays a role in EAE severity and therapeutic response (Xu et al., 2025).

Evidence & Benchmarks

• MOG (35-55) induces severe, chronic EAE in C57BL/6 and NOD/Lt mice at doses between 50–150 μg (subcutaneous, with CFA) (Xu et al., 2025).
• Administration results in relapsing-remitting neurological deficits, demyelinating lesions, and immune cell infiltration, mimicking human MS pathology (Pelubiprofenshop, 2023).
• MOG (35-55) peptide stock solutions are soluble at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO; insoluble in ethanol (APExBIO).
• In vitro, the peptide is effective at concentrations up to 50 μg/mL with 48-hour incubation, reliably activating T cells (Mouse-IL, 2023).
• MOG (35-55)-driven EAE is associated with dose-dependent increases in NADPH oxidase and MMP-9 activities, supporting its use in oxidative stress and matrix remodeling studies (Xu et al., 2025).
• Inhibition of PARP7, a regulator of type I interferon signaling, alleviates EAE symptoms induced by MOG (35-55), identifying therapeutic targets (Xu et al., 2025).

This article extends the peptide benchmarking and troubleshooting guidance in IGH-1 (2023) by providing detailed, citation-backed mechanisms and integration with interferon signaling data.

Applications, Limits & Misconceptions

Core Applications:

• Establishing robust EAE models for preclinical MS research.
• Screening immunomodulatory and neuroprotective drugs.
• Dissecting T and B cell-mediated autoimmunity and CNS demyelination.
• Evaluating oxidative stress pathways and matrix metalloproteinase activity.

MOG (35-55) from APExBIO is validated for use in HLA-DR2-transgenic, NOD/Lt, and C57BL/6 mice but not all mouse strains or non-rodent species (APExBIO).

Common Pitfalls or Misconceptions

• Non-specific induction: MOG (35-55) is not suitable for modeling MS in species lacking compatible MHC-II alleles.
• Peptide degradation: Stock solutions must be stored desiccated at −20°C and used promptly to avoid loss of activity (APExBIO).
• Vehicle incompatibility: The peptide is insoluble in ethanol and should be prepared in sterile water or DMSO.
• Over-interpretation: EAE models induced by MOG (35-55) do not fully recapitulate all clinical subtypes of human MS (IMHC, 2023).
• Protocol drift: Small changes in adjuvant or dosing can lead to variable disease severity (IMHC, 2023).

Workflow Integration & Parameters

For MOG (35-55) Peptide (SKU A8306), prepare stock solutions in sterile water at 0.50 mg/mL, using gentle warming and ultrasonic shaking to enhance solubility. Store lyophilized peptide desiccated at −20°C. Typical in vitro concentrations range from 0–50 μg/mL for up to 48 hours. For in vivo induction of EAE in mice, inject 50–150 μg subcutaneously with CFA. Monitor disease onset, progression, and immune cell infiltration using standardized neurological scoring and histopathology (Mouse-IL, 2023). For oxidative stress and matrix remodeling studies, assess NADPH oxidase and MMP-9 activities post-induction. This article clarifies peptide handling and mechanistic integration compared to Pelubiprofenshop (2023), which provides a general benchmark overview.

Conclusion & Outlook

MOG (35-55) peptide remains the gold-standard tool for inducing EAE in preclinical MS research. Its robust, reproducible immune activation supports studies into neuroinflammation, autoimmunity, and therapeutic intervention. Recent insights into type I interferon signaling and PARP7 regulation offer new avenues for MS drug discovery (Xu et al., 2025). Adherence to validated protocols and consideration of model limitations are essential for translational impact. For further optimization and troubleshooting, see scenario-driven integration guides (IMHC, 2023).